Daré Bioscience (DARE) Investor update summary

Strategic focus and portfolio overview

• Solely dedicated to women's health, addressing gaps from contraception to menopause and infectious disease.

• Commercial and development-stage products are all clinically backed, with a focus on real-world solutions.

• Significant use of non-dilutive grant funding to advance the pipeline, minimizing reliance on equity capital.

• Portfolio includes both prescription and non-prescription products, leveraging multiple market entry paths.

Commercialization and product launches

• Flora Sync LF5, a vaginal probiotic, launched in July and is available via the Daré Health Hub and clinician offices.

• DARE to PLAY Sildenafil Cream, a first-of-its-kind arousal cream for women, is set to begin dispensing this quarter as a 503B compounded product.

• Commercial strategy leverages provider relationships, telehealth, and digital channels for direct patient engagement.

• The Daré Health Hub serves as a central platform for prescriptions, fulfillment, and cross-selling opportunities.

Development pipeline and upcoming catalysts

• Ovaprene, a non-hormonal monthly contraceptive, is in pivotal phase III with top-line data expected next year; development is grant-funded.

• DARE-HPV, a pharmacologic intervention for HPV infection, is in phase II with data readout expected next year, fully supported by ARPA-H grant.

• Menopause hormone therapy product aims for commercialization next year as a 503B compounded product, with additional non-hormonal and fertility products in early-stage development.

• Multiple clinical and commercial catalysts are anticipated this year and next, supporting a capital-efficient growth strategy.